EKF moves to make inroads in molecular Dx market

03/4/2013 | Clinica (subscription required)

EKF Diagnostics has agreed to acquire 360 Genomics, which specializes in mutation detection technology, for $2.4 million worth of company stock and as much as $12.1 million in milestone cash payments. The deal will allow EKF to expand its point-of-care testing portfolio as well as make inroads in the molecular diagnostics arena.

View Full Article in:

Clinica (subscription required)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA